| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100490 | Best Practice & Research Clinical Haematology | 2010 | 5 Pages |
Abstract
There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2Â ÃÂ 106Â CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5Â ÃÂ 106Â CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
John F. (Professor of Medicine and Immunology and Pathology),